A Phase 2 Multicenter Randomized Clinical Trial of Ciliary Neurotrophic Factor (CNTF) for Macular Telangiectasia Type 2 (MacTel)
Phase of Trial: Phase II
Latest Information Update: 29 Jun 2017
At a glance
- Drugs NT 501 (Primary)
- Indications Retinal telangiectasis
- Focus Therapeutic Use
- Sponsors GNT Pharma
- 26 Jun 2017 Status changed from active, no longer recruiting to completed.
- 20 Jun 2017 Results published in a Neurotec Pharma media release.
- 20 Jun 2017 Primary endpoint (Ellipsoid zone (area of IS/OS loss) as measured by en face imagining by SDOCT in study eye(s)) has been met according to a Neurotec Pharma media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History